161. Wilson M. R. et al. Frontline management of nodular lymphocyte predominant Hodgkin lymphoma-a retrospective UK multicentre study //British journal of haematology. - 2019.
162. Eichenauer DA, Fuchs M. Treatment of Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Where Do We Stand? Where Do We Go? Cancers (Basel). 2023 Jun 23;15(13):3310.
163. Sandra Purz, Christine Mauz-Ko¨rholz, Dieter Ko¨rholz, et al. [18F] Fluorodeoxyglucose positron emission tomography for detection of bone marrow involvement in children and adolescents with Hodgkin’s Lymphoma. Journal of Clinical Oncology, volume 29, number 26, 3523 - 3528 (2011
164. Aamna Hassan, Maimoona Siddique, Humayun Bashir, et al. [18F]-FDG PET-CT imaging versus bone marrow biopsy in pediatric Hodgkin’s lymphoma: a quantitative assessment of marrow uptake and novel insights into clinical implications of marrow involvement. Eur J Nucl Med Mol Imaging (2017) 44:1198-1206
165. Christopher J. Forlenza, Jaclyn Rosenzweig, et al. Brentuximab vedotin after autologous transplantation in pediatric patients with relapsed/refractory Hodgkin lymphoma. Blood Adv (2023) 7 (13): 3225-3231.
166. Sara Ebrahimi, Adrina Habibzadeh, Soroush Khojasteh-Kaffash et al., Immune checkpoint inhibitors therapy as the game-changing approach for pediatric lymphoma: A brief landscape. Critical Reviews in Oncology/Hematology, volume 193 (2024), 104225
167. Christopher L Tinkle, Noelle L Williams, Huiyun Wu, et al. Treatment patterns and disease outcomes for pediatric patients with refractory or recurrent Hodgkin lymphoma treated with curative-intent salvage radiotherapy. Radiother Oncol. 2019 Feb 5;134:89-95
168. C Mauz-Körholz, T Lange, D Hasenclever, B Burkhardt, A C Feller, W Dörffel et al. Pediatric Nodular Lymphocyte-predominant Hodgkin Lymphoma: Treatment Recommendations of the GPOH-HD Study Group. Klin Padiatr. (2015); 227(6-7):314-21.
169. Dennis A. Eichenauer, Andreas Engert. How I treat nodular lymphocyte-predominant Hodgkin lymphoma. Blood (2020) 136 (26): 2987-2993.
170. David C. Hodgson MD, Karin Dieckmann MD, Stephanie Terezakis, Louis Constine. Implementation of contemporary radiation therapy planning concepts for pediatric Hodgkin lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group. Practical Radiation Oncology, volume 5, issue 2 (2015), pages 85-92
171. Marr K, Ronsley R, Nadel H, Douglas K, Gershony S, Strahlendorf C, Davis JH, Deyell RJ. Ifosfamide, gemcitabine, and vinorelbine is an effective salvage regimen with excellent stem cell mobilization in relapsed or refractory pediatric Hodgkin lymphoma. Pediatr Blood Cancer. 2020 Apr;67(4):e28167. doi: 10.1002/pbc.28167. Epub 2020 Jan 11.
172. Algeri M, Locatelli F. Pembrolizumab (and friends) in pediatric malignancies: should we consider Hodgkin lymphoma a world of its own? Ann Transl Med. 2020 Sep;8(17):1112. doi: 10.21037/atm.2020.04.54.
173. Галстян Г.М. Инфузионная терапия у пациентов с гематологическими заболеваниями // Сопроводительная терапия при лечении заболеваний системы крови. Под редакцией Е.Н. Паровичниковой, Г.М. Галстян. 2024. P. 495-501.
174. Камельских Д.В. et al. Трансфузии донорской крови и (или) ее компонентов у взрослых пациентов с гематологическими заболеваниями. // Сопроводительная терапия при лечении заболеваний системы крови. Под редакцией Е.Н. Паровичниковой, Г.М. Галстяна. ИД "Практика". 2024. P. 387-407.
175. Галстян Г.М., Спирин М.В. Сосудистый доступ в гематологии // ИД “Практика.” 2021. P. 232.
176. Воробьев А.И. et al. Критические состояния при гемобластозах (типичные формы и выживаемость в условиях отделения реанимации). // Терапевтический архив. 1993. Vol. 65, № 7. P. 3-6.
177. Галстян Г.М., Городецкий В.М. Опыт работы отделения реанимации и интенсивной терапии ФГБУ ГНЦ МЗиСР РФ // Клиническая онкогематология. 2011. Vol. 4, № 1. P. 75-78.
178. Vuolio T., Kuittinen O., Väyrynen J.P., Teppo H., Prusila R.E.I., Rämet M., Kuitunen H., Paloneva T., Kuusisto M.E.L. R-bendamustine in the Treatment of Nodular Lymphocyte Predominant Hodgkin Lymphoma-An Extended Follow-up. Br. J. Haematol. 2023 doi: 10.1111/bjh.18896
179. Gotti M., Sciarra R., Pulsoni A., Merli F., Luminari S., Zerbi C., Trentin L., Re A., Rusconi C., Viviani S., et al. Role of Rituximab Addition to First-Line Chemotherapy Regimens in Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi. HemaSphere. 2023;7:e837. doi: 10.1097/HS9.0000000000000837.
180. Pusic I, Jiang SY, Landua S, Uy GL, Rettig MP, Cashen AF, Westervelt P, Vij R, Abboud CN, Stockerl-Goldstein KE, et al. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant. 2008;14:1045-1056. doi: 10.1016/j.bbmt.2008.07.004
181. Gertz, M., Wolf, R., Micallef, I. et al. Clinical impact and resource utilization after stem cell mobilization failure in patients with multiple myeloma and lymphoma. Bone Marrow Transplant 45, 1396-1403 (2010) .doi.org/10.1038/bmt.2009.370
182. Zheng G, He J, Cai Z, He D, Luo Y, Shi J, Wei G, Sun J, Zheng W. A retrospective study of autologous stem cell mobilization by G-CSF in combination with chemotherapy in patients with multiple myeloma and lymphoma. Oncol Lett. 2020 Jan;19(1):1051-1059. doi: 10.3892/ol.2019.11177
183. "Lymphocyte-Predominant Hodgkin's Disease in Children: A Case Study and Review of the Literature". James R Stier, Robert J Vasquez. Case Rep Oncol Med. 2015 Mar 24; 2015: 351431. doi:10.1155/2015/351431
184. "Nodular lymphocyte predominant Hodgkin lymphoma in children and adolescents - a comprehensive review of biology, clinical course and treatment options". Ananth Shankar and Stephen Daw. British Journal of Haematology, 2012. doi:10.1111/bjh.12055
185. "Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma". Santoro A., Magagnoli M., Spinа M et al. 2007. Haematologica 92(1):35-41.